Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform
By Ben Glickman
Shares of Co-Diagnostics rose on Wednesday after the company submitted an application to the Food and Drug Administration for its Covid-19 test platform.
The stock was up 21% to $1.39 in midday trading. Shares are down 46% this year.
The Salt Lake City-based company said it had submitted its Co-Dx PCR Covid-19 test to the FDA for Emergency Use Authorization. The company's submission includes its PCR Pro instrument, the Covid-19 detection test and an associated mobile app.
Co-Diagnostics said its polymerase chain reaction technology has been shown in evaluations to detect Covid-19 in nasal swabs with results shown on the app within 30 minutes.
The company is also developing its Co-Dx platform to test for tuberculosis, HPV and certain other respiratory viruses.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 27, 2023 12:52 ET (17:52 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom